Dr. Subramaniam is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
3800 Reservoir Road Nw
Podium A Lombardi
Washington, DC 20007Phone+1 202-444-2223Fax+1 202-444-7009- Is this information wrong?
Summary
Education & Training
- MedStar Health/Georgetown University HospitalFellowship, Hematology and Medical Oncology, 2004 - 2007
- Providence HospitalResidency, Internal Medicine, 1999 - 2002
- University of WashingtonMS, 1995 - 1997
- Kilpauk Medical CollegeClass of 1993
Certifications & Licensure
- DC State Medical License 2004 - 2020
Awards, Honors, & Recognition
- Top Fundraising Team Award Race for Hope - DC, 2017
- Triumph of the Spirit Award for Excellence in Brain Tumor Care The Rabbi Joseph Weinberg Foundation, 2014
- Teaching Excellence Award Georgetown University, 2013
- Join now to see all
Clinical Trials
- A Study of Prexasertib (LY2606368) in Participants With Extensive Stage Disease Small Cell Lung Cancer Start of enrollment: 2016 May 11
- Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches Start of enrollment: 2014 Nov 01
- Lung-MAP: Palbociclib as Second-Line Therapy in Treating Cell Cycle Gene Alteration Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer Start of enrollment: 2014 Sep 01
- Join now to see all
Publications & Presentations
PubMed
- 20 citationsSafety, tolerability and efficacy of agonist anti-CD27 antibody (varlilumab) administered in combination with anti-PD-1 (nivolumab) in advanced solid tumors.Rachel E Sanborn, Michael J Pishvaian, Margaret K Callahan, Amy Weise, Branimir I Sikic, Osama Rahma, Daniel C Cho, Naiyer A Rizvi, Mario Sznol, Jose Lutzky, Julie E B...> ;Journal for Immunotherapy of Cancer. 2022 Aug 1
- 9 citationsA Phase I Trial of Dasatinib and Osimertinib in TKI Naïve Patients With Advanced EGFR-Mutant Non-Small-Cell Lung Cancer.Chul Kim, Stephen V. Liu, Jennifer Crawford, Tisdrey Torres, Vincent Chen, Jillian Thompson, Ming Tan, Giuseppe Esposito, Deepa S. Subramaniam, Giuseppe Giaccone> ;Frontiers in Oncology. 2021 Sep 8
- Real-world impact of brain metastases on healthcare utilization and costs in patients with non-small cell lung cancer treated with EGFR-TKIs in the USAmanda M Kong, Melissa Pavilack, Hairong Huo, Rahul Shenolikar, Meghan Moynihan, Elizabeth Hoit Marchlewicz, Christina Chebili-Larson, Stella Min, Deepa S. Subramaniam> ;Journal of Medical Economics. 2021 Mar 1
- Join now to see all
Authored Content
- CME Course Non -Small Cell Lung Cancer5/9/2016
Press Mentions
- Increased Infection Rates Associated with Tetracycline Therapy Given for Epidermal Growth Factor Receptor Inhibitor (EGFRI)-Associated Acneiform Eruption: A Retrospective Study of Data from Two Cancer CentersJuly 4th, 2019
- OncLive® Presents the Latest State of the Science Summit™ on Advances in Lung Cancer ManagementOctober 29th, 2018
- No Increase in Brain Tumors Seen from Cell PhonesDecember 3rd, 2009
Committees
- Chairman, GU Hem-Onc Fellow Program Education Committee 2016 - Present
Professional Memberships
- Member
Other Languages
- Tamil, Hindi
External Links
- IASLC Endorsed Lung Cancer CMEhttps://medstar.cloud-cme.com/aph.aspx?P=5&EID=2777#
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: